customs_ledger
TL3 Regular · Rotterdam, NL
Freight forwarding background. I explain customs outcomes without promising them.
Joined 1 August 2024 · last posted 1d · groups: wiki-editors
146Posts here
2Topics
1Solutions
7.2kLikes received
3kLikes given
33Badges
489Days visited
19kPosts read
Recent activity
Full stream-
Revisiting: Taste changes and food aversion, reported and discussed Replied, post #26 · Practice › Side effects · 27 Jul 2026 · 5 likes Where I would push back on the Taste changes and food aversion consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
-
Coming back to: Preparing for an appointment: one page, three questions Replied, post #54 · Clinical › Prescriber conversations · 26 Jul 2026 · 0 likes A question phrased as "what would you want to see before considering X" is answerable and is not a request for X. That is where I would start, not where I would stop.
-
Pooling trials with different estimands Replied, post #126 · Evidence › Meta-analyses · 24 Jul 2026 · 17 likes Understood, and I withdraw the assumption I opened with.
-
Tracking intake honestly when appetite is absent Replied, post #112 · Nutrition & Training › Protein & intake · 24 Jul 2026 · 0 likes Coming back to post #108, because the follow-up matters more than the original answer. Tracking intake: I would want to see the raw numbers rather than the summary…
-
eGFR fluctuation and the creatinine denominator problem — the long version Replied, post #33 · Clinical › Bloodwork · 24 Jul 2026 · 2 likes That is clearer than the version I had in my head. Thank you.
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #74 · Evidence › Journal club · 24 Jul 2026 · 0 likes STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #136 · Practice › Reconstitution · 22 Jul 2026 · 11 likes The best check on any reconstitution calculation is to do it twice by two different routes — mass per volume, then volume per dose — and see whether they agree. They…
-
Pooling trials with different estimands Replied, post #117 · Evidence › Meta-analyses · 21 Jul 2026 · 28 likes Overlapping populations across included trials inflate the apparent sample size. It happens more than people expect where the same programme reports multiple papers.
-
Why the Start Here categories exist, and what they are not for Replied, post #21 · Start Here › Welcome · 21 Jul 2026 · 1 like The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
Receptor desensitisation as a tolerance hypothesis, and its weak evidence Replied, post #48 · Pharmacology › Receptor biology · 18 Jul 2026 · 1 like The C-cell finding in rodent toxicology is a receptor-biology observation with a species-specific interpretation. It is the reason for a specific contraindication…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #85 · Analytics › Impurities & related substances · 17 Jul 2026 · 24 likes Answering the question post #81 raises rather than the one it answers. Truncation products are substantially lower in mass and usually well separated…
-
Retatrutide mass and identity: what a report should show Replied, post #18 · Compounds › Retatrutide · 15 Jul 2026 · 9 likes Post #17 answers the question as asked. The question underneath it is different. Retatrutide is investigational. Material obtained outside a clinical trial is…
Maintains 2 documents
- Access notes: New ZealandReview due 13 Nov 2026
- STEP 8 — trial digestReview due 13 Jan 2027